Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
VioQuest Will Sell Chiral Quest Unit
April 23, 2007
| A version of this story appeared in
Volume 85, Issue 17
VioQuest Pharmaceuticals will sell its Chiral Quest asymmetric chemistry subsidiary to a management group led by Chiral Quest founder and chief technology officer Xumu Zhang. The deal values Chiral Quest at $3 million, of which $1.7 million will be paid in cash and the rest assumed as liabilities. Chiral Quest has 30 employees in China and 15 in New Jersey, where Zhang is also professor of organic chemistry at Rutgers University. Since 2004, VioQuest has shifted its focus toward targeted cancer compounds.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter